hormone dependent neoplasms


Summary: Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.

Top Publications

  1. Wang G, Wang J, Sadar M. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res. 2008;68:9918-27 pubmed publisher
    ..These studies provide the first in vivo evidence to support aberrant activation of the AR through the Wnt/beta-catenin signaling pathway during progression of prostate cancer to the terminal castrate-resistant stage...
  2. Journe F, Body J, Leclercq G, Laurent G. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health. Expert Opin Drug Saf. 2008;7:241-58 pubmed
    ..We conclude that, because of its therapeutic efficacy and its seemingly minimal effect on bone integrity, fulvestrant represents a new option for the hormonal treatment of breast cancer that deserves further clinical evaluation...
  3. Rizzo P, Miao H, D Souza G, Osipo C, Song L, Yun J, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 2008;68:5226-35 pubmed publisher
    ..Our data indicate that combinations of antiestrogens and Notch inhibitors may be effective in ERalpha(+) breast cancers and that Notch signaling is a potential therapeutic target in ERalpha(-) breast cancers...
  4. Raghavan D, Klein E. Prostate cancer: moving forward by reinventing the wheel...but this time it is round. J Clin Oncol. 2008;26:4535-6 pubmed publisher
  5. Chen J, Brown T, Yager J. Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria. Adv Exp Med Biol. 2008;630:1-18 pubmed
  6. Attard G, Reid A, Yap T, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563-71 pubmed publisher
    ..To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued...
  7. Fehm T, Krawczyk N, Solomayer E, Becker Pergola G, Dürr Störzer S, Neubauer H, et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res. 2008;10:R76 pubmed publisher
    ..Of particular interest is their oestrogen-receptor (ER) status because endocrine adjuvant therapy remains a cornerstone of breast cancer treatment...
  8. Coleman R, Bolten W, Lansdown M, Dale S, Jackisch C, Merkel D, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev. 2008;34:275-82 pubmed
    ..Knowing that joint symptoms can be managed in most patients may encourage patient-physician communication and treatment compliance...
  9. Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-81 pubmed publisher
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...

More Information

Publications109 found, 100 shown here

  1. McCall P, Gemmell L, Mukherjee R, Bartlett J, Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer. 2008;98:1094-101 pubmed publisher
  2. Duffy S, Distler W, Howell A, Cuzick J, Baum M. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol. 2009;200:80.e1-7 pubmed publisher
    ..Results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial have shown that tamoxifen is associated with a significantly higher incidence of gynecologic adverse events than anastrozole...
  3. Straver M, Rutgers E, Rodenhuis S, Linn S, Loo C, Wesseling J, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17:2411-8 pubmed publisher
    ..Although in ER-positive tumors the pCR rate is low, the increase in breast-conserving surgery was remarkable in ductal ER-positive tumors. ..
  4. Aiyer H, Gupta R. Berries and ellagic acid prevent estrogen-induced mammary tumorigenesis by modulating enzymes of estrogen metabolism. Cancer Prev Res (Phila). 2010;3:727-37 pubmed publisher
    ..05). Berries may prevent mammary tumors by suppressing the levels of E(2)-metabolizing enzymes during the early phase of E(2) carcinogenesis...
  5. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin L, Wan X, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008;68:8039-48 pubmed publisher
    ..Subsequent progression of tumors was associated with reactivation of p-AKT despite sustained suppression of IGF-IR. These results identified the first predictive biomarker for anti-IGF-IR therapies in cancer. ..
  6. Attard G, Reid A, A Hern R, Parker C, Oommen N, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742-8 pubmed publisher
    ..CYP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven. ..
  7. Wolff J. Chemotherapy in hormone-refractory prostate cancer. Front Radiat Ther Oncol. 2008;41:103-7 pubmed publisher
    ..Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years. ..
  8. Yang J, Ok J, Busby J, Borowsky A, Kung H, Evans C. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res. 2009;69:151-60 pubmed publisher
    ..This xenograft model shows autocrine, neuropeptide- and Src kinase-mediated progression of androgen-independent CaP postcastration, and is potentially useful for testing novel therapeutic agents. ..
  9. Teixeira A, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, et al. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 2009;9:341-6 pubmed publisher
    ..Combined blockage of key molecules in proliferation signaling pathways could be one of the most promising strategies for androgen-independent prostate cancer. ..
  10. Dalenc F, Doisneau Sixou S, Allal B, Marsili S, Lauwers Cances V, Chaoui K, et al. Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. Clin Cancer Res. 2010;16:1264-71 pubmed publisher
    ..Nevertheless, the identified peptide could be of interest in discriminating, at 8 weeks of treatment, responders from nonresponders. ..
  11. Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S, et al. Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol. 2008;617:529-34 pubmed publisher
    ..The importance of the LBD/AF-2 for the regulation of AR transcriptional activities, the impact of the presence of such AR variants on PC cells proliferation and survival, and on progression to androgen independence are discussed. ..
  12. Radice S, Chiesara E, Fucile S, Marabini L. Different effects of PCB101, PCB118, PCB138 and PCB153 alone or mixed in MCF-7 breast cancer cells. Food Chem Toxicol. 2008;46:2561-7 pubmed publisher
    ..On the contrary the mixture of PCBs induces an antiproliferative effect, ascribable to an apoptotic action. ..
  13. Campbell E, McDuff E, Tatarov O, Tovey S, Brunton V, Cooke T, et al. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer. 2008;99:1769-74 pubmed publisher
    ..Further study is required in ER-negative breast cancer as this may represent a cohort in which it is associated with poor outcome. ..
  14. Colleoni M, Sun Z, Martinelli G, Basser R, Coates A, Gelber R, et al. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol. 2009;20:1344-51 pubmed publisher
    ..Further studies designed to confirm the importance of endocrine responsiveness in patients treated with dose-intensive chemotherapy are encouraged. ..
  15. Hussain Hakimjee E, Mehta R. Regulation of steroid receptor expression by 1alpha-hydroxyvitamin D5 in hormone-responsive breast cancer cells. Anticancer Res. 2009;29:3555-61 pubmed
    ..Although no VDR stabilization by 1alpha(OH)D5 was observed, there was an increased expression of the VDR followed by partial anti-estrogenic activity in hormone-responsive BT-474 cells. ..
  16. Smith L, Coleman L, Cummings M, Satheesha S, Shaw S, Speirs V, et al. Expression of oestrogen receptor beta isoforms is regulated by transcriptional and post-transcriptional mechanisms. Biochem J. 2010;429:283-90 pubmed publisher
    ..In addition, we demonstrate how 17beta-oestradiol, a key driver of breast cancer development, affects the regulation of ERbeta expression at both transcriptional and translational levels. ..
  17. Izumi K, Mizokami A, Shima T, Narimoto K, Sugimoto K, Kobori Y, et al. Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer. Anticancer Res. 2010;30:3077-81 pubmed
    ..The survival rates at 12 and 24 months were 74.5% and 61.5%, respectively. Although this study involved only pilot data, it indicates that tranilast may improve the prognosis of patients with advanced CRPC. ..
  18. Pissimissis N, Papageorgiou E, Lembessis P, Armakolas A, Koutsilieris M. The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res. 2009;29:371-7 pubmed
    ..GS, EAAT1 and mGLuR5 were also detected at the protein level in both PC-3 and LNCAP cells. These data suggest that the Glu system could be an important regulator of prostate cancer cell biology. ..
  19. Byrne C, Divekar S, Storchan G, Parodi D, Martin M. Cadmium--a metallohormone?. Toxicol Appl Pharmacol. 2009;238:266-71 pubmed publisher
  20. Terakawa T, Miyake H, Furukawa J, Ettinger S, Gleave M, Fujisawa M. Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer. 2009;101:1731-9 pubmed publisher
    ..Excessive secretion of IL-6 by LNCaP cells in an autocrine manner may have a suppressive function in their growth and acquisition of androgen-independent phenotype under an androgen-deprived condition. ..
  21. Butterworth K, McCarthy H, Devlin A, Ming L, Robson T, McKeown S, et al. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer. 2008;123:760-8 pubmed publisher
    ..This study shows that hypoxia can select for androgen independent prostate cancer cells which have a survival advantage and are more likely to invade and metastasize. ..
  22. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena F, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010;16:1904-14 pubmed publisher
    ..Further investigation of epidermal growth factor receptor inhibition in combination with endocrine therapy may be warranted. ..
  23. Li C, Chlebowski R, Freiberg M, Johnson K, Kuller L, Lane D, et al. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. J Natl Cancer Inst. 2010;102:1422-31 pubmed publisher
    ..Alcohol use may be more strongly associated with risk of hormone-sensitive breast cancers than hormone-insensitive subtypes, suggesting distinct etiologic pathways for these two breast cancer subtypes. ..
  24. Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res (Phila). 2009;2:518-24 pubmed publisher
    ..Ongoing studies using a systems biology approach in a preoperative prostate cancer setting are testing this hypothesis toward developing more-rational clinical interventions. ..
  25. Donovan M, Osman I, Khan F, Vengrenyuk Y, Capodieci P, Koscuiszka M, et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int. 2010;105:462-7 pubmed publisher
  26. Tesan T, Gustavsson H, Welén K, Damber J. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models. BJU Int. 2008;102:1034-9 pubmed publisher
  27. Shah M, Kriedt C, Lents N, Hoyer M, Jamaluddin N, Klein C, et al. Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res. 2009;28:84 pubmed publisher
    ..Thus, our studies form a solid proof-of-concept that direct intra-tumoral injection of zinc acetate could be a safe and effective treatment strategy for prostate cancer. ..
  28. Gradishar W, Hansen N, Susnik B. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice. Clin Adv Hematol Oncol. 2009;7:1-7 pubmed
    ..Also, the latest research into the benefit of the Oncotype DX assay in node-positive patients is discussed. Finally, sample case studies offer clinically relevant examples of the practical application of the Oncotype DX assay. ..
  29. Bollet M, Savignoni A, de Koning L, Tran Perennou C, Barbaroux C, Degeorges A, et al. Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment. Breast Cancer Res. 2009;11:R54 pubmed publisher
    ..Our results highlight the role of estrogen-signaling pathways (mainly CYP19/aromatase, GATA3, and ER-beta) in the risk of locoregional recurrence of breast cancer in young women. Confirmation in larger prospective studies is needed. ..
  30. Berstein L. Role of endocrine-genotoxic switchings in cancer and other human diseases: basic triad. Adv Exp Med Biol. 2008;630:35-51 pubmed
    ..The measures to correct components of the 'triad' can be divided into several groups aimed to optimally orchestrate the balance between endocrine and DNA-damagingeffects of estrogens, glucose and adipose tissue-related factors. ..
  31. Matsubara A, Teishima J, Mirkhat S, Yasumoto H, Mochizuki H, Seki M, et al. Restoration of FGF receptor type 2 enhances radiosensitivity of hormone-refractory human prostate carcinoma PC-3 cells. Anticancer Res. 2008;28:2141-6 pubmed
    ..These results indicate that restoration of FGFR2IIIb to PC-3 cells enhances their sensitivity to irradiation through acceleration of apoptosis and cell cycle arrest. ..
  32. Freedman G, Anderson P, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009;115:946-51 pubmed publisher
    ..2%, respectively; P = .36) between the 3 groups. Patients with TN breast cancer do not appear to be at a significantly increased risk for isolated LRR at 5 years and therefore remain appropriate candidates for breast conservation. ..
  33. Woditschka S, Haag J, Sullivan R, Gould M. A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas. Cancer Prev Res (Phila). 2009;2:153-60 pubmed publisher
    ..Our prevention model represents a cost-efficient in vivo system to determine whether the preventive effects of a compound extend to hormonally nonresponsive mammary lesions, for which new chemoprevention approaches are needed...
  34. Gustavsson H, Wang W, Jennbacken K, Welén K, Damber J. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer. BJU Int. 2009;104:1786-90 pubmed publisher
    ..Further, ADAMTS1 might have an anti-angiogenic and antimetastatic role in hormone-refractory prostate cancer, where low ADAMTS1 expression is associated with a high MVD and metastasis. ..
  35. Carlesimo B, Tempesta M, Fioramonti P, Bistoni G, Ruggiero M, Marchetti F. [Breast cancer metastasis in distal phalanx of the big toe. Case report]. G Chir. 2009;30:487-9 pubmed
    ..X-rays and MRI showed a lucent area of bone destruction on the shaft of the distal phalanx of the left big toe. Surgical biopsy on the excised bone assessed for breast cancer metastasis. ..
  36. Hayashi S, Yamaguchi Y. Estrogen signaling pathway and hormonal therapy. Breast Cancer. 2008;15:256-61 pubmed publisher
    ..Furthermore, we touch upon basic studies into predicting the efficacy of hormonal therapy and new strategies in this field. ..
  37. Takayama K, Tsutsumi S, Suzuki T, Horie Inoue K, Ikeda K, Kaneshiro K, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res. 2009;69:137-42 pubmed publisher
    ..Our findings will indicate that APP could be a potential molecular target for the diagnosis and treatment of prostate cancer. ..
  38. Vis A, Schroder F. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009;104:438-48 pubmed publisher
    ..Additionally, CRPCs might synthesise AR isoforms that enable AR mediated processes independent from available androgens. ..
  39. Etique N, Grillier Vuissoz I, Lecomte J, Flament S. Crosstalk between adenosine receptor (A2A isoform) and ERalpha mediates ethanol action in MCF-7 breast cancer cells. Oncol Rep. 2009;21:977-81 pubmed
    ..These results demonstrate cross-talk between A2AAR and ERalpha that is involved in ethanol action. This could open new perspectives for the therapy of estrogen-dependent breast cancer. ..
  40. Secreto G, Venturelli E, Meneghini E, Greco M, Ferraris C, Gion M, et al. Testosterone and biological characteristics of breast cancers in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2009;18:2942-8 pubmed publisher
    ..The relationship between testosterone and HER2 status in the oldest patients merits further investigation. ..
  41. Yamaguchi Y, Hayashi S. Estrogen-related cancer microenvironment of breast carcinoma. Endocr J. 2009;56:1-7 pubmed
    ..In this paper, we discuss the importance of tumor-stromal crosstalk in breast cancers, and describe our system to predict the efficacy of endocrine therapy and to analyze estrogen signals in individual breast cancers. ..
  42. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone Donnorso R, et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 2008;10:R74 pubmed publisher
    ..In this context, further investigations are necessary to better assess the role of the different ER-beta isoforms. ..
  43. Milne R, Benitez J, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, et al. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst. 2009;101:1012-8 pubmed publisher
    ..15, 95% CI = 1.11 to 1.19; P = 5 x 10(-14)) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002). The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women. ..
  44. Aguero M, Venero M, Brown D, Smulson M, Espinoza L. Phenoxodiol inhibits growth of metastatic prostate cancer cells. Prostate. 2010;70:1211-21 pubmed publisher
  45. Nakano Y, Bilim V, Yuuki K, Muto A, Kato T, Nagaoka A, et al. Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation. Prostate Cancer Prostatic Dis. 2009;12:34-40 pubmed publisher
    ..Our results identify the adaptability of PCa cells to chronic loss of XIAP in part through upregulation of Bcl-2 and indicate that multitargeting approach is the most effective application in the chemotherapy of human HRPC. ..
  46. Abdulhaq H, Geyer C. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Am J Clin Oncol. 2008;31:595-605 pubmed publisher
  47. Wang D, Montgomery R, Schmidt L, Mostaghel E, Huang H, Nelson P, et al. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res. 2009;69:9448-56 pubmed publisher
  48. Mumenthaler S, Rozengurt N, Livesay J, Sabaghian A, Cederbaum S, Grody W. Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate. 2008;68:1561-9 pubmed publisher
    ..However, the biological function of arginase II in prostate cancer still remains to be elucidated. In this study, we utilized the TRAMP mouse prostate cancer model to better understand the contribution of AII on tumor development...
  49. Schilling D, Kufer R, Kruck S, Stenzl A, Kuczyk M, Merseburger A. [Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?]. Urologe A. 2008;47:1334-8 pubmed publisher
    ..We discuss the mode of action and application of somatostatin analogs as an emerging secondary hormonal treatment concept in patients with advanced prostate cancer on the basis of the current literature...
  50. Nelson C, Lee J, Gamboa M, Roth A. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113:1097-106 pubmed publisher
  51. Erten C, Karaca B, Kucukzeybek Y, Gorumlu G, Cengiz E, Gul M, et al. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int. 2009;104:107-14 pubmed publisher
  52. Hortobagyi G, Brown P. Two good choices to prevent breast cancer: great taste, less filling. Cancer Prev Res (Phila). 2010;3:681-5 pubmed publisher
    ..For 12 years, the public has avoided Food and Drug Administration-approved tamoxifen or raloxifene for breast cancer risk reduction; it is time to reemphasize the great preventive benefit of these agents to the public...
  53. Takayanagi A, Masumori N, Hashimoto J, Kyoda Y, Yanase M, Tsukamoto T. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy. Jpn J Clin Oncol. 2010;40:1154-8 pubmed publisher
    ..We analyzed the efficacy of additional antiandrogens as second- and third-line treatments after the failure of initial androgen deprivation monotherapy...
  54. Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, et al. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis. 2008;29:2341-6 pubmed publisher
    ..083/0.037). These findings indicate that genetic variants in FGFR2 may contribute to breast cancer occurrence in Chinese women, possibly through pathways related to estrogen and/or progesterone...
  55. Anborgh P, Wilson S, Tuck A, Winquist E, Schmidt N, Hart R, et al. New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem. 2009;55:895-903 pubmed publisher
    ..We compared both assays with 4 assays that recognize defined regions of OPN protein (dual polyclonal systems 5-1, 4-1, 4-3 and polyclonal-monoclonal system 1-3)...
  56. Sasaki T, Nakamura K, Ogawa K, Onishi H, Okamoto A, Koizumi M, et al. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan. BJU Int. 2009;104:1462-6 pubmed publisher
    ..To evaluate the clinical results of radiotherapy (RT) for patients with regionally localized hormone-refractory prostate carcinoma (HRPC)...
  57. Musgrove E, Sutherland R. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9:631-43 pubmed publisher
    ..The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic...
  58. Zheng Y, Zhang J, Xu Z, Sheng J, Zhang X, Wang H, et al. Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues. J Zhejiang Univ Sci B. 2010;11:144-50 pubmed publisher
    ..To investigate the mechanisms behind this paradox, we determined the differences between the transcriptional profiles of ER-alpha36 and full-length ER-alpha (ER-alpha66) in breast cancers and matched normal tissues...
  59. Loi S, Haibe Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A. 2010;107:10208-13 pubmed publisher
    ..In ER+ BC cell lines, PIK3CA mutations were also associated with sensitivity to tamoxifen. These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors...
  60. Stark A, Kleer C, Martin I, Awuah B, Nsiah Asare A, Takyi V, et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 2010;116:4926-32 pubmed publisher
    ..The study of breast cancer in women with African ancestry offers the promise of identifying markers for risk assessment and treatment of triple-negative disease...
  61. Lin H, Lu J, Laflamme P, Qiao S, Shayegan B, Bryskin I, et al. Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies. Int J Oncol. 2010;37:761-6 pubmed
    ..These results therefore support the rationale for PC prevention using 5-alpha reductase inhibitors, dietary restrictions or anti-oxidants, each of which has different inhibitory but complementary effects...
  62. Thangapazham R, Shaheduzzaman S, Kim K, Passi N, Tadese A, Vahey M, et al. Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biol Ther. 2008;7:1427-35 pubmed
    ..Importantly, new gene-networks identified here further delineate molecular mechanism(s) of action of curcumin in prostate cancer cells...
  63. Suzuki R, Orsini N, Saji S, Key T, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis. Int J Cancer. 2009;124:698-712 pubmed publisher
    ..The relation between body weight and breast cancer risk is critically dependent on the tumor's ER/PR status and the woman's menopausal status. Body weight control is the effective strategy for preventing ER+PR+ tumors after menopause...
  64. Rebbeck T, DeMichele A, Tran T, Panossian S, Bunin G, Troxel A, et al. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis. 2009;30:269-74 pubmed publisher
    ..We further report that these genes confer their effects in HER2- tumors, interact with one another to confer breast cancer susceptibility in AA women and interact with hormone exposures in AA and EA women...
  65. Ortmann O, Cufer T, Dixon J, Maass N, Marchetti P, Pagani O, et al. Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast. 2009;18:2-7 pubmed publisher
    ..This report summarizes the conclusions and recommendations that arose from this discussion...
  66. Madan R, Mohebtash M, Schlom J, Gulley J. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther. 2010;10:19-28 pubmed publisher
    ..Those principles need to be applied to future trial design to properly evaluate prostate cancer vaccines...
  67. Rajpar S, Massard C, Laplanche A, Tournay E, Gross Goupil M, Loriot Y, et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol. 2010;21:1864-9 pubmed publisher
    ..The aim of this study was to assess the prognostic value of uNTx for overall survival (OS) and the incidence of SRE in patients with bone metastases from CRPC receiving zoledronic acid...
  68. Rennert G, Pinchev M, Rennert H. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28:3577-81 pubmed publisher
    ..However, the association between the use of bisphosphonates and the risk of developing breast cancer has not been reported...
  69. Tessel M, Krett N, Rosen S. Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol. 2010;22:592-7 pubmed publisher
    ..Therefore, elucidating miRNA regulation of SHR expression and modulation of miRNAs by SHRs may provide diagnostic biomarkers or therapeutic targets...
  70. Badve S, Baehner F, Gray R, Childs B, Maddala T, Liu M, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473-81 pubmed publisher
  71. Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int. 2008;102:617-21 pubmed publisher
  72. Gong H, Jarzynka M, Cole T, Lee J, Wada T, Zhang B, et al. Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res. 2008;68:7386-93 pubmed publisher
    ..Because glucocorticoids and estrogens are widely prescribed drugs, our results also urge caution in avoiding glucocorticoid-estrogen interactions in patients...
  73. Kim S, Singh S. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Mol Cancer Ther. 2009;8:1946-54 pubmed publisher
    ..In conclusion, the present study shows for the first time that SFN treatment causes transcriptional repression of AR and inhibition of its nuclear localization in human prostate cancer cells...
  74. Yasufuku T, Shigemura K, Matsumoto O, Arakawa S, Fujisawa M. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. J Infect Chemother. 2010;16:200-5 pubmed publisher
  75. Siegfried J. Early changes in pulmonary gene expression following tobacco exposure shed light on the role of estrogen metabolism in lung carcinogenesis. Cancer Prev Res (Phila). 2010;3:692-5 pubmed publisher
    ..Actions of estrogens that contribute to lung carcinogenesis, especially in the presence of tobacco smoke, may involve both reactive intermediates that damage DNA and steroid hormone receptor signaling that promotes growth...
  76. Chen S, Ye J, Kijima I, Evans D. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A. 2010;107:11032-7 pubmed publisher
    ..3/II. These findings provide an important basis for future clinical evaluations of LBH589 in hormone-dependent breast cancer...
  77. Gillessen S, Templeton A, Marra G, Kuo Y, Valtorta E, Shahinian V. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010;102:1760-70 pubmed publisher
    ..In animal studies, androgens protect against colonic carcinogenesis, suggesting that androgen deprivation may increase the risk of colorectal cancer...
  78. Goyal S, Puri T, Julka P, Rath G. Excellent response to letrozole in brain metastases from breast cancer. Acta Neurochir (Wien). 2008;150:613-4; discussion 614-5 pubmed publisher
    ..This report suggests that letrozole has beneficial effects both in extracranial and intracranial disease in hormone responsive metastatic breast cancer...
  79. Rocha R, Nunes C, Rocha G, Oliveira F, Sanches F, Gobbi H. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry. Pathol Res Pract. 2008;204:655-62 pubmed publisher
    ..The novel rabbit antibodies against ER and PR are highly sensitive for immunohistochemical testing of breast carcinomas...
  80. Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo V, Burow M, et al. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat. 2009;118:33-43 pubmed publisher
    ..Organic selenium may provide added benefit when combined with tamoxifen in adjuvant therapy or prevention...
  81. Cos S, Gonzalez A, Martinez Campa C, Mediavilla M, Alonso Gonzalez C, Sanchez Barcelo E. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 2008;8:691-702 pubmed
  82. Bertaccini A, Pernetti R, Marchiori D, Pagotto U, Palladoro F, Palmieri F, et al. Variations in blood ghrelin levels in prostate cancer patients submitted to hormone suppressive treatment. Anticancer Res. 2009;29:1345-8 pubmed
    ..The aim of this study is to assess the relationship existing between ghrelin and testosterone, insulin, and PSA in prostate adenocarcinoma...
  83. Nualart F, Los Angeles García M, Medina R, Owen G. Glucose transporters in sex steroid hormone related cancer. Curr Vasc Pharmacol. 2009;7:534-48 pubmed
    ..Finally, an insight into the use of glucose transporters as markers of cancer progression and clinical outcome is also discussed...
  84. Fejerman L, Haiman C, Reich D, Tandon A, Deo R, John E, et al. An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:3110-7 pubmed publisher
    ..However, we found little evidence that genetic ancestry at any one region contributes significantly to breast cancer risk or hormone receptor status...
  85. Milecki P, Baczyk M, Skowronek J, Antczak A, Kwias Z, Martenka P. Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. J Biomed Biotechnol. 2009;2009:625394 pubmed publisher
    ..To study whether use of neoadjuvant androgen deprivation therapy (N-ADT) combined with whole pelvic radiotherapy (WPRT) for high-risk prostate cancer patients was associated with survival benefit over prostate radiotherapy (PORT) only...
  86. Miura N, Numata K, Kusuhara Y, Shirato A, Hashine K, Sumiyoshi Y. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. Jpn J Clin Oncol. 2010;40:1092-8 pubmed publisher
    ..To evaluate the efficacy and toxicity of docetaxel plus prednisolone treatment in Japanese patients with hormone-refractory prostate cancer (HRPC)...
  87. Namiki M, Kitagawa Y, Mizokami A, Koh E. Primary combined androgen blockade in localized disease and its mechanism. Best Pract Res Clin Endocrinol Metab. 2008;22:303-15 pubmed publisher
    ..We propose algorithms for the treatment of localized prostate cancer not only in low- and intermediate-risk groups but also in the high-risk group...
  88. Ang J, Olmos D, de Bono J. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100:671-5 pubmed publisher
  89. Liu G, Taylor S, Marrinan C, Hsieh Y, Bishop W, Kirschmeier P, et al. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. Int J Cancer. 2009;125:2711-20 pubmed publisher
    ..An intermittent dosing schedule of lonafarnib coadministered with docetaxel may allow enhanced efficacy to that of continuous dosing by improving the tolerability of higher doses of lonafarnib...
  90. Alaoui Jamali M, Bismar T, Gupta A, Szarek W, Su J, Song W, et al. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009;69:8017-24 pubmed publisher
    ..A potent synergistic activity was observed when OB-24 was combined with Taxol. Together, these results establish HO-1 as a potential therapeutic target for advanced PCA...
  91. Ko E, Lee B, Kim H, Noh W, Kim M, Lee S. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol. 2010;20:1111-7 pubmed publisher
  92. Rizzi F, Bettuzzi S. The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer. 2010;17:R1-17 pubmed publisher
    ..High expression of secreted or cytoplasmic CLU may represent a pro-survival stimulus because it confers increased resistance to killing by anti-cancer drugs or enhances tumour cell survival in specific niches...